447 related articles for article (PubMed ID: 11221016)
21. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
23. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
[TBL] [Abstract][Full Text] [Related]
24. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N; Nakagawa K; Nishimura Y; Tsujino K; Satouchi M; Kudo S; Hida T; Kawahara M; Takeda K; Katakami N; Sawa T; Yokota S; Seto T; Imamura F; Saka H; Iwamoto Y; Semba H; Chiba Y; Uejima H; Fukuoka M
J Clin Oncol; 2010 Aug; 28(23):3739-45. PubMed ID: 20625120
[TBL] [Abstract][Full Text] [Related]
25. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
28. [Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)].
Nakabayashi T; Miyamoto H; Fujikane T; Shimizu T; Yasuda S; Akita H; Sakai E; Onodera S; Ohsaki Y; Kawakami Y
Gan To Kagaku Ryoho; 1992 Jan; 19(1):61-7. PubMed ID: 1309633
[TBL] [Abstract][Full Text] [Related]
29. [A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group].
Nagao K; Fukuoka M; Fujita A; Kurita Y; Saito R; Niitani H; Negoro S; Katakami N; Nakano M
Gan To Kagaku Ryoho; 2000 Mar; 27(3):413-21. PubMed ID: 10740635
[TBL] [Abstract][Full Text] [Related]
30. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan plus cisplatin in small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):39-43. PubMed ID: 12375800
[TBL] [Abstract][Full Text] [Related]
32. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
Kodani T; Ueoka H; Kiura K; Tabata M; Takigawa N; Segawa Y; Moritaka T; Hiraki S; Harada M; Tanimoto M
Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Kim HT; Han JY; Lee DH; Chun JH; Lee HG; Lee JJ; Kim HY; Lee SY; Lee JS
Cancer; 2006 Aug; 107(4):799-805. PubMed ID: 16826586
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 1999; 56(4):301-7. PubMed ID: 10343194
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
[TBL] [Abstract][Full Text] [Related]
38. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan in advanced lung cancer: focus on North American trials.
Langer CJ
Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]